What question did this study set out to answer?

This study aims to evaluate the predictive value of splenic imaging in anticipating myelosuppression during treatment for small cell lung cancer.

March 29, 2026Open Access

18FAlF-NOTA-QHY-04 uptake in spleen before anti-tumor therapy may predict degree of myelosuppression for patients with small cell lung cancer

Key Points

This study aims to evaluate the predictive value of splenic imaging in anticipating myelosuppression during treatment for small cell lung cancer.
Conducted PET/CT scans using [18F]AlF-NOTA-QHY-04 in 59 patients with SCLC before therapy.
Measured uptake parameters: SUVmax, SUVmean, SUVpeak, metabolic tumor volume, and total lesion CXCR4 expression.
Recorded severity of myelosuppression during chemotherapy.
Analyzed intergroup differences, ROC curves, and performed multivariate analysis.
Patients with severe myelosuppression had significantly higher splenic uptake values (SUVmax, SUVmean, SUVpeak, TLC) than those with mild myelosuppression (p < 0.05).
Higher metabolic parameters were associated with severe myelosuppression (e.g., SUVmax AUC = 0.853).
SUVmax and age emerged as significant predictors of treatment-related myelosuppression severity.

Abstract

The aim of this study was to assess the value of C-X-C motif chemokine receptor 4 (CXCR4) targeted positron emission tomography/computed tomography (18FAlF-NOTA-QHY-04 PET/CT) imaging in spleen for prediction of degree of myelosuppression in patients with small cell lung cancer (SCLC) before therapy. 59 patients with SCLC underwent 18FAlF-NOTA-QHY-04 PET/CT scanning before treatment. The maximum, mean, and peak standard uptake value (SUVmax, SUVmean, SUVpeak), metabolic tumor volume (MTV) and total lesion CXCR4 expression (TLC) of spleen at baseline were acquired. Chemotherapy-based treatment was administered for limited-stage and extensive-stage SCLC. The most severe degree of myelosuppression during the treatment was recorded. Patients were identified as mild and severe myelosuppression. Potential predictors were identified and validated through intergroup difference analysiis, ROC curve assessment, and ordinal regression analysis. Patients with severe myelosuppression exhibited significantly higher splenic uptake values (SUVmax, SUVmean, SUVpeak and TLC) compared to those with mild myelosuppression (all p < 0.05). Regions of interest (ROI) curve analysis identified that higher metabolic parameters, including SUVmax (AUC = 0.853, p < 0.0001), SUVmean (AUC = 0.885, p < 0.0001), SUVpeak (AUC = 0.821, p < 0.0001), TLC (AUC = 0.753, p = 0.0016), were significantly associated with more severe myelosuppression. Multivariate analysis identified SUVmax (p = 0.007) and age (p = 0.005) as significant independent predictors of treatment-related myelosuppression severity. Our findings suggest that baseline splenic 18FAlF-NOTA-QHY-04 PET/CT parameters, particularly SUVmax, may help identify patients with small cell lung cancer who are at high risk of severe treatment-related myelosuppression, with older age serving as an additional clinical risk factor.

Perguntar à IA

Bookmark

View Full Paper